Verona pharma to announce top-line data from phase 3 enhance-1 trial of nebulized ensifentrine for copd

London and raleigh, n.c., dec. 19, 2022 (globe newswire) -- verona pharma plc (nasdaq: vrna) (“verona pharma” or the "company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line phase 3 data from its enhance-1 trial of nebulized ensifentrine on tuesday, december 20, 2022. the company will host an investment community webcast and conference call at 8:30 a.m. est / 1:30 p.m. gmt to discuss these data.
VRNA Ratings Summary
VRNA Quant Ranking